{
  "id": 16097996,
  "title": "Moderna plummets 24% after unverified leaks about its melanoma vaccine",
  "url": "https://urgent.news/2026/10/22/moderna-se-desploma-un-24-tras-filtraciones-no-verificadas-sobre-su",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-22T19:23:17.000Z",
  "source": {
    "name": "Expansion ES",
    "slug": "expansion-es",
    "url": "https://www.expansion.com/mercados/2026/10/22/6ada62a1468aeb866d8b4572.html"
  },
  "original_language": "es",
  "account": "Moderna's shares plummeted up to 24% to $187.6 after closing at $245.81, following a report on social media X that its melanoma vaccine, developed with Merck, did not meet expectations. The report claimed a 42% reduction in cancer recurrence or death, but the link to the report was inactive. Previous studies showed the vaccine reduced recurrence or death risk by 49% and metastasis or death risk by 59%. The vaccine combines an RNA therapy with Merck's Keytruda.",
  "summary": "The biotechnology company's shares fell to $187.6 after closing the previous session at $245.81.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}